health
Liver Health Support
Liver Health Support describes an intervention’s relationship with liver-related wellness, commonly assessed through changes in a liver biomarker such as ALT. It is not a single symptom that a person necessarily notices, and it should not be confused with a diagnosis or a guarantee of improved liver health.
See how Liver Health Support is organized and review its wellness context in one concise, easy-to-navigate reference.
These are research findings, not promises. Most options have little evidence, and results differ from person to person.
What may help
What studies found for each option, best evidence first.
8 options:1 good evidence1 some evidence1 mixed2 not enough evidence2 not tested in people1 personal stories only
Strength TrainingpracticeGood evidence it helpsSize of effect: Not known
Good human studies found a benefit, and they mostly agree. This is about what studies measured, not a cure.
All 3 studies with a clear result found a benefit. Strongest study: a pooled analysis of several trials.
A pooled analysis whose study designs were not recorded found resistance exercise reduced ALT by −15.40 IU/L in patients with MASLD/MASH, among 136 people in its outcome analysis. Another pooled analysis reported a decrease of −4.44 U/L.
Open the Strength Training pageHigh-Intensity Interval Training (HIIT)practiceSome evidence it helpsSize of effect: Medium
Some human studies found a benefit. More research could change this.
All 6 studies with a clear result found a benefit. Strongest study: a pooled analysis of several trials.
A pooled analysis of randomized trials involving 87 people found a reduction in intrahepatic lipid. Another pooled analysis involving 1,546 people reported improvements in liver markers.
Open the High-Intensity Interval Training (HIIT) pageFastingpracticeMixed resultsSize of effect: Not known
Studies disagree: some found a benefit, others found none. Do not count on it.
8 of 10 studies found a benefit; 2 found none. Strongest study: a pooled analysis of several trials.
Open the Fasting pageCupping TherapypracticeNot enough evidence
Too few or too small studies to know if it works.
The one study found a benefit. Strongest study: a randomized controlled trial.
Open the Cupping Therapy pageTabata TrainingpracticeNot enough evidence
Too few or too small studies to know if it works.
The one study found a benefit. Strongest study: a non-randomized trial.
A 2025 quasi-experimental study of 40 participants with obesity found a decrease in SGOT of 4.51 U/L.
Open the Tabata Training pageChagasupplementNot tested in people
Only tested in animals, cells or theory. Results like these often do not carry over to people.
3 of 4 studies found a benefit; 1 found none. Strongest study: an animal study. Studied for 13 weeks.
In an animal model, the liver score was significantly lower versus the DB group, indicating reduced steatosis and fibrosis.
Open the Chaga pageTurkey TailsupplementNot tested in people
Only tested in animals, cells or theory. Results like these often do not carry over to people.
The one study found a benefit. Strongest study: an animal study. Studied for 4 weeks.
Open the Turkey Tail pageSea Moss (Irish Moss)supplementOnly personal stories
Only people's own stories online. No study has tested it.
Based on one study.
Open the Sea Moss (Irish Moss) page
Comparing practices
- Strength TrainingGood evidence it helps3 trials
- High-Intensity Interval Training (HIIT)Some evidence it helpsSize of effect: Medium6 trials
- FastingMixed results6 trials
The expert view shows every study, dose protocol and source.
What may help
Linked to improving it8 listedStart here
Highest probability, strongest evidence
- →PracticesStrength TrainingCertaintyHighSourceMeta-analysis3 other sources
A pooled analysis whose study designs were not recorded found resistance exercise reduced ALT by −15.40 IU/L in patients with MASLD/MASH, among 136 people in its outcome analysis. Another pooled analysis reported a decrease of −4.44 U/L.
Who was studied
- People with a condition
Open Strength TrainingStudy result
resistance exercise reduced ALT (WMD = −15.40 IU/L, 95%CI −28.60 to −2.20, P < 0.001) in patients with MASLD/MASH compared to the control group
Medium probability(2)(0)(2)
- →PracticesFastingCertaintyMediumSourceMeta-analysisconflicting findings10 other sources
A meta-analysis of randomized trials involving 1,149 people found that time-restricted fasting was the most effective regimen for reducing hepatic steatosis (MD: -23.32 dB/m), followed by the 5:2 Diet. Another pooled analysis of randomized and non-randomized human studies reported a reduction in serum AST (mean difference: −5.27 IU/L, 95% CI: −7.88 to −2.67), but results varied considerably between studies; a separate pooled analysis found no significant difference in MRI-PDFF between intermittent fasting and continuous energy restriction.
Who was studied
- Healthy people and patients
- Cancer
- Diabetes Type2
- Fatty Liver Nafld
- Hepatitis Viral
- Obesity
Open FastingStudy result
TRF was the most effective regimen for reducing hepatic steatosis (MD: -23.32 dB/m), followed by the 5:2 Diet
- →PracticesHigh-Intensity Interval Training (HIIT)CertaintyMediumSourceRCTModerate effect6 other sources
A pooled analysis of randomized trials involving 87 people found a reduction in intrahepatic lipid. Another pooled analysis involving 1,546 people reported improvements in liver markers.
How big is the effect
Moderate effectA clear difference on average.
Who was studied
- Healthy people and patients
- Asthma
- Cancer
- Copd
- Coronary Artery Disease
- Diabetes Type2
- Fatty Liver Nafld
- +7 more
Open High-Intensity Interval Training (HIIT)Study result
HIIT significantly improved 12 outcomes vs. controls, including liver markers (-1.06 to -0.50)
Low probability(3)(1)(2)
- →PracticesCupping TherapyCertaintyLowSourceClinical1 other source
In a trial of 120 people with non-alcoholic fatty liver disease, ALT levels decreased more in the intervention group than in the comparison group (MD -4.12 IU/L).
Who was studied
- People with a condition
- Fatty Liver Nafld
Open Cupping TherapyStudy result
serum levels of ALT (–6.50 ± 4.92 vs –2.38 ± 3.92, P < 0.001)
- →PracticesTabata TrainingCertaintyLowSourceClinical1 other source
A 2025 quasi-experimental study of 40 participants with obesity found a decrease in SGOT of 4.51 U/L (95% CI = −5.58 to −3.44).
Who was studied
- People with a condition
- Obesity
Open Tabata TrainingStudy result
SGOT [T = −4.51 U/L (95% CI = −5.58 to −3.44; p < 0.001)]
- →SupplementsChagaCertaintyLowSourceAnimal researchanimal / in-vitro only4 other sources
In an animal model, the liver score was significantly lower versus the DB group (p<0.01), indicating reduced steatosis and fibrosis.
Who was studied
- Diabetes Type2
- Dyslipidemia
- Obesity
Dose & course
13 weeks
Who it applies to
- Animal
Open ChagaStudy result
Reduced area and severity of steatosis qualitatively; no quantification reported
Very low probability(2)(2)(0)
- →SupplementsTurkey TailCertaintyVery lowSourceAnimal researchanimal / in-vitro only1 other source
Improved serum liver function indices, dose-dependent (specific markers and values not reported in abstract)
Who was studied
- People with a condition
- Diabetes Type2
Dose & course
4 weeks
Open Turkey TailWho it applies to
- Animal
- →SupplementsSea Moss (Irish Moss)CertaintyVery lowSourceAnecdotal1 other source
This effect was mentioned in 2 of 250 Reddit reports discussing it.
Practices compared
Practices with at least one trial of their own for this goal. Ranked by how sure the evidence is, then effect size.| Practice | How sure | Effect size | Own trials | What worked in trials |
|---|---|---|---|---|
| Strength Training | CertaintyHighSourceMeta-analysis | 3 trials or pooled analyses | 3×/week · 12–15 weeks | |
| High-Intensity Interval Training (HIIT) | CertaintyMediumSourceRCT | Moderate effect | 6 trials or pooled analyses | 28–29 min · 2.5–3×/week · 4–8 weeks |
| Fasting | CertaintyMediumSourceMeta-analysis | 6 trials or pooled analyses | 4–28 weeks | |
| Cupping Therapy | CertaintyLowSourceClinical | 1 trial or pooled analysis | ||
| Tabata Training | CertaintyLowSourceClinical | 1 trial or pooled analysis |
What worked in trials: From the smallest to the typical amount in the trials that found this benefit. Not the most anyone did, not a target and not a limit.
How to read the evidence
Evidence tier — overall strength of the evidence for the whole compound
- StrongWell established — backed by strong, consistent human research.
- ModerateSome genuine support, but mostly from small or lower-quality studies. Promising, not proven.
- PreliminaryEarly-stage evidence — a promising hypothesis, not an established effect yet.
- LimitedVery limited evidence — treat this as a hypothesis, not proof.
- InsufficientNot enough good evidence to draw conclusions yet.
Certainty — how sure we can be that the effect is real
- Very highVery sure — strong, consistent evidence
- HighFairly sure — consistent evidence from good studies
- MediumModerately sure — new studies could change this
- LowNot sure — little or mixed evidence
- Very lowVery unsure — almost no usable evidence
Source — where the data comes from
- Meta-analysisPooled analysis of many trials — the strongest evidence
- RCTRandomized controlled trial — a strong human study design
- ClinicalA human clinical study
- Reference knowledgeFrom general health-science or pharmacology references, not a study of this exact claim
- Animal researchStudied in animals, not humans
- Community reportsAggregated user reports — anecdotal signal, not evidence
- TheoreticalMechanism-based reasoning, not yet tested
Study grade — quality of each underlying study (A best, D weakest)
- AHigh-quality — strong, consistent human trials
- BGood — solid evidence with some limitations
- CModerate — limited, small, or mixed-quality studies
- DWeak — preliminary, indirect, or animal-only
Confidence — how strongly the sources back a finding
A 0–100 score from study quality and agreement
Most supplement evidence is graded C–D. Read it as preliminary signal, not proof.
Full write-up
What is it
Liver Health Support describes an intervention’s relationship with liver-related wellness, commonly assessed through changes in a liver biomarker such as ALT. It is not a single symptom that a person necessarily notices, and it should not be confused with a diagnosis or a guarantee of improved liver health. The outcome brings together evidence from several types of interventions and reflects measured changes rather than one universal experience.
How interventions help
The interventions studied for Liver Health Support primarily affect ALT, a liver-related biomarker, rather than covering every aspect of liver health. Across the research, changes were generally assessed after several weeks or months. Some studies evaluated shorter courses, such as 2-12 weeks, while Vitamin E was studied over 2 to 24 months. This means the findings describe measured changes during defined study periods, not necessarily effects that persist after stopping.
Study amounts varied substantially between interventions. For example, Chlorella was studied at 135-15000 mg/day, Vitamin E at 298-1000 IU/day, and Curcumin at 1000 mg twice daily. These are research ranges rather than general recommendations. Some interventions were assessed with daily use, while others did not require continuous daily use in the reported studies. Berberine was associated with an onset category of days, whereas Saffron Extract was categorized as taking weeks; these categories do not establish how quickly every person will respond.
The evidence does not apply equally across all interventions or populations. Omega-3 was studied in people with several metabolic and liver-related conditions, whereas many other interventions were studied in unspecified populations. Some findings come from human research, while others rely on animal studies or lack human evidence. ALT changes also do not automatically demonstrate improvement in liver structure: for example, the overall finding for Omega-3 was inconclusive for fibrosis, and the reviewed Ginger finding included changes in several measures alongside diet and physical-activity advice. Results are therefore best read as intervention-specific biomarker findings, with differences in study duration, population, and outcome.
Choosing guidance
When choosing among these options, first decide whether human evidence is essential. Vitamin E and Garlic have direct human research, while several other options, including Omega-3, Milk Thistle (Silymarin), Chlorella, and Curcumin, also have human studies but differ in consistency and outcomes. The findings generally concern changes in liver-related biomarkers; they should not automatically be interpreted as proof that liver disease or fibrosis will improve.
Study regimens vary widely. Some options were examined over short periods, while others were used for several months or longer, and the tested doses and preparations are not interchangeable. This matters particularly for Garlic, Curcumin, Omega-3, and products whose formulation differs substantially between studies. A product is more relevant when its preparation, amount, and duration resemble those used in the research.
Interpret disagreement carefully. Milk Thistle (Silymarin), Omega-3, and Chlorella have findings that are not fully consistent, while Resveratrol and several other options rely mainly on animal or nonclinical evidence. Animal-only, reference-based, or anecdotal options may be of interest for research purposes, but they are a poor fit for someone seeking established human evidence. Options with very limited human research are best viewed as uncertain rather than as interchangeable alternatives.